Literature DB >> 30189065

Blunt Abdominal Trauma, Splenectomy, and Post-Splenectomy Vaccination.

Zsolt Stockinger1, Daniel Grabo1, Avi Benov1, Homer Tien1, Jason Seery1, Ashley Humphries1.   

Abstract

Unlike penetrating abdominal injuries where the decision to operate is relatively straight forward, those combat casualties that sustain blunt abdominal trauma offer more of a diagnostic and clinical challenge. For unstable patients with a positive focused abdominal sonography in trauma or diagnostic peritoneal lavage, exploratory laparotomy should be undertaken immediately. All grade IV-V splenic injuries should undergo splenectomy, patients undergoing attempted splenic salvage should be monitored in the Role 3 facility and embolization of such splenic injuries may be considered if available. Patients who fail non-operative management of the spleen require splenectomy at the Role 3 prior to aeromedical evacuation. Overwhelming post-splenectomy infection is a serious disease that can progress from a mild flu-like illness to fulminant sepsis in a short period of time. Although relatively rare, it has a high mortality rate with delayed or inadequate treatment. All splenectomized patients and those deemed to be functionally asplenic should be vaccinated within 14 days from splenectomy and prior to aeromedical evacuation.

Entities:  

Mesh:

Year:  2018        PMID: 30189065     DOI: 10.1093/milmed/usy095

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

Review 1.  Splenic marginal zone lymphoma: a case report and literature review.

Authors:  Shiyu Zhang; Zefeng Xuan; Liang Zhang; Jiahua Lu; Penghong Song; Shusen Zheng
Journal:  World J Surg Oncol       Date:  2020-10-01       Impact factor: 2.754

Review 2.  Laparoscopic splenectomy after trauma: Who, when and how. A systematic review.

Authors:  Pietro Fransvea; Gianluca Costa; Angelo Serao; Francesco Cortese; Genoveffa Balducci; Gabriele Sganga; Pierluigi Marini
Journal:  J Minim Access Surg       Date:  2021 Apr-Jun       Impact factor: 1.407

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.